When it comes to Biogen’s controversial Alzheimer’s drug Aduhelm, even publishing the data is steeped in drama.
The key data that led to Aduhelm’s approval by the Food and Drug Administration were finally published Wednesday, more than two years after they were first described in a press release.
But in a highly irregular step for an important clinical trial, the data were published not in a major journal but in the little-known Journal of the Prevention of Alzheimer’s Disease. That has critics worried that Biogen has found a low-stakes forum for a study that deserves scrutiny and debate.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
